Ulinastatin

乌司他丁

Report date: 2023/02/27 09:47:08
NME

Base Information

Drug NameUlinastatin
Drug Alias Nameulinastatina乌司他汀Urinastatin乌斯他丁ulinastatine +[17] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTrypsin inhibitors
TargetsTrypsin
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Acutely decompensated congestive heart failureRespiratory Distress Syndrome, Adult +[5] 
Global Approved IndicationsAcutely decompensated congestive heart failurePancreatitis
Approved Indications in ChinaAcutely decompensated congestive heart failurePancreatitis
Original Approved Country/TerritoryJapan
Original Approved Date1994/07/01
Country/TerritoryUnited StatesMainland ChinaJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesTechpool Bio-Pharma Co LtdMochda Pharmaceutical Co Ltd
Inactive CompaniesStanford University
Active IndicationsAcutely decompensated congestive heart failurePancreatitis
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, AdultAcute Lung Injury

Other Information

ATC CodeB02AB05
Related LinksWikipediaKEGG